NASDAQ:LKFT Lakefront Biotherapeutics American Depositary Shares (LKFT) Stock Price, News & Analysis $28.55 -0.36 (-1.25%) As of 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Lakefront Biotherapeutics American Depositary Shares Stock (NASDAQ:LKFT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get LKFT alerts:Sign Up Key Stats Today's Range$28.51▼$29.1150-Day Range$26.08▼$30.0152-Week Range$25.68▼$37.78Volume459,127 shsAverage Volume251,104 shsMarket Capitalization$1.88 billionP/E RatioN/ADividend YieldN/APrice Target$30.67Consensus RatingHold Company Overview Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium. Read More Lakefront Biotherapeutics American Depositary Shares Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks21st Percentile Overall ScoreLKFT MarketRank™: Lakefront Biotherapeutics American Depositary Shares scored higher than 21% of companies evaluated by MarketBeat, and ranked 832nd out of 905 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.6 / 5Analyst RatingHold Consensus RatingLakefront Biotherapeutics American Depositary Shares has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 strong buy rating, 1 buy rating, 7 hold ratings, and no sell ratings.Upside/DownsideThe consensus price target for Lakefront Biotherapeutics American Depositary Shares is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageLakefront Biotherapeutics American Depositary Shares has only been the subject of 4 research reports in the past 90 days.Read more about Lakefront Biotherapeutics American Depositary Shares' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Lakefront Biotherapeutics American Depositary Shares are expected to decrease in the coming year, from ($1.27) to ($1.80) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Lakefront Biotherapeutics American Depositary Shares is -20.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Lakefront Biotherapeutics American Depositary Shares is -20.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLakefront Biotherapeutics American Depositary Shares has a P/B Ratio of 0.60. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted5.15% of the float of Lakefront Biotherapeutics American Depositary Shares has been sold short.Short Interest Ratio / Days to CoverLakefront Biotherapeutics American Depositary Shares has a short interest ratio ("days to cover") of 14, which indicates bearish sentiment.Change versus previous monthShort interest in Lakefront Biotherapeutics American Depositary Shares has recently increased by 10.84%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldLakefront Biotherapeutics American Depositary Shares does not currently pay a dividend.Dividend GrowthLakefront Biotherapeutics American Depositary Shares does not have a long track record of dividend growth. News and Social Media2.3 / 5News Sentiment0.61 News SentimentLakefront Biotherapeutics American Depositary Shares has a news sentiment score of 0.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.80 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Lakefront Biotherapeutics American Depositary Shares this week, compared to 3 articles on an average week. Company Ownership0.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Lakefront Biotherapeutics American Depositary Shares insiders have not sold or bought any company stock.Percentage Held by Insiders2.91% of the stock of Lakefront Biotherapeutics American Depositary Shares is held by insiders.Percentage Held by Institutions32.46% of the stock of Lakefront Biotherapeutics American Depositary Shares is held by institutions.Read more about Lakefront Biotherapeutics American Depositary Shares' insider trading history. Receive LKFT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lakefront Biotherapeutics American Depositary Shares and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. LKFT Stock News HeadlinesLakefront Biotherapeutics NV (LKFT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeptember 17 at 1:24 AM | seekingalpha.comAcquisition of Own SharesSeptember 15 at 4:01 PM | globenewswire.comShocking new footage just releasedGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he says has never existed before. In a similar setup in the past, select investors saw $1,000 turn into over $1 million within a few years. Del Real just released a full video breakdown of what is driving this move and how to prepare.September 18 at 1:00 AM | Digest Publishing (Ad)Lakefront Biotherapeutics: A Cash Discount With A More Credible Path To ValueSeptember 15 at 9:47 AM | seekingalpha.comBrokerages Set Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) Price Target at $30.67September 10, 2026 | americanbankingnews.comAcquisition of Own SharesSeptember 8, 2026 | globenewswire.comLakefront to Present at the Morgan Stanley 24th Annual Global Healthcare ConferenceSeptember 8, 2026 | globenewswire.comAcquisition of Own SharesSeptember 1, 2026 | globenewswire.comSee More Headlines LKFT Stock Analysis - Frequently Asked Questions How have LKFT shares performed this year? Lakefront Biotherapeutics American Depositary Shares' stock was trading at $32.70 at the beginning of 2026. Since then, LKFT stock has decreased by 12.7% and is now trading at $28.55. How were Lakefront Biotherapeutics American Depositary Shares' earnings last quarter? Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) released its quarterly earnings results on Monday, August, 10th. The biotechnology company reported $0.04 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.97) by $1.01. The biotechnology company had revenue of $15.47 million for the quarter, compared to analyst estimates of $7.29 million. How do I buy shares of Lakefront Biotherapeutics American Depositary Shares? Shares of LKFT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Lakefront Biotherapeutics American Depositary Shares own? Based on aggregate information from My MarketBeat watchlists, some other companies that Lakefront Biotherapeutics American Depositary Shares investors own include American Water Works (AWK), Humana (HUM), Waste Connections (WCN), Voyager Therapeutics (VYGR), The RMR Group (RMR), DiamondRock Hospitality (DRH) and AUO (AUOTY). Company Calendar Last Earnings8/10/2026Today9/18/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (5m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 LKFT's financial health is in the Red zone, according to TradeSmith. LKFT has been in this zone for over 5 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:LKFT Previous SymbolNASDAQ:GLPG CIK1421876 Webwww.glpg.com Phone(321) 534-2900Fax321-534-2901Employees1,310Year Founded1999Price Target and Rating Average Price Target for Lakefront Biotherapeutics American Depositary Shares$30.67 High Price Target$40.00 Low Price Target$26.00 Potential Upside/Downside+7.4%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio32.84 Quick Ratio32.72 Sales & Book Value Annual Sales$1.26 billion Price / Sales1.50 Cash Flow$0.72 per share Price / Cash Flow39.82 Book Value$47.57 per share Price / Book0.60Miscellaneous Outstanding Shares65,900,000Free Float63,979,000Market Cap$1.88 billion OptionableOptionable Beta0.28 Social Links 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NASDAQ:LKFT) was last updated on 9/18/2026 by MarketBeat.com Staff. From Our PartnersA “bloodbath” Is ComingReports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...TradeSmith | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | SponsoredShocking new footage just releasedGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...Digest Publishing | SponsoredIran War WARNING: Something Just ChangedA powerful Middle Eastern government is reportedly asking Trump for U.S. military help against Iran backed for...Banyan Hill Publishing | Sponsored$747 million in one quarter - with a 60% cash-flow targetThe company posted $747 million in net income last quarter and plans to return at least 60% of 2026 free cash ...Monument Traders Alliance | SponsoredWhy I went to Mount RushmoreA small miner just hit on gold in the hills surrounding Mount Rushmore, thanks to a breakthrough new technolog...Stansberry Research | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lakefront Biotherapeutics American Depositary Shares Please log in to your account or sign up in order to add this asset to your watchlist. Share Lakefront Biotherapeutics American Depositary Shares With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free LKFT Stock Alerts